Edgar Filing: OMNICELL, Inc

Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________________________________________________________________

FORM 10-Q



(Mark One)
ý	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2018
OR
o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to

Commission File No. 000-33043

OMNICELL, INC.

(Exact name of registrant as specified in its charter)



Delaware (State or other jurisdiction of incorporation or organization)	94-3166458 (IRS Employer Identification No.)

590 East Middlefield Road

Mountain View, CA 94043

(Address of registrant’s principal executive offices, including zip code)

(650) 251-6100

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ý No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer ý	Accelerated filer o	Non-accelerated filer o (Do not check if a smaller reporting company)	Smaller reporting company o	Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transitions period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.				o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No ý

As of July 26, 2018, there were 39,269,970 shares of the registrant’s common stock, $0.001 par value, outstanding.

Table of Contents

OMNICELL, INC.

TABLE OF CONTENTS



		Page
PART I	FINANCIAL INFORMATION
Item 1.	Condensed Consolidated Financial Statements (Unaudited)	3
	Condensed Consolidated Balance Sheets as of June 30, 2018 and December 31, 2017	3
	Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2018 and June 30, 2017	4
	Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and six months ended June 30, 2018 and June 30, 2017	5
	Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2018 and June 30, 2017	6
	Notes to Condensed Consolidated Financial Statements	7
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	27
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	40
Item 4.	Controls and Procedures	40

PART II	OTHER INFORMATION	42
Item 1.	Legal Proceedings	42
Item 1A.	Risk Factors	42
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	58
Item 3.	Defaults Upon Senior Securities	58
Item 4.	Mine Safety Disclosures	58
Item 5.	Other Information	58
Item 6.	Exhibits	59

Signatures		60

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

OMNICELL, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)



	June 30, 2018			December 31, 2017
	(In thousands, except par value)
	(In thousands, except par value)
ASSETS
Current assets:
Cash and cash equivalents	$	46,168		$	32,424
Accounts receivable and unbilled receivables, net of allowances of $5,341 and $5,738, respectively	174,570			190,046
Inventories, net	103,732			96,137
Prepaid expenses	18,266			20,392
Other current assets	16,122			13,273
Total current assets	358,858			352,272
Property and equipment, net	50,884			42,595
Long-term investment in sales-type leases, net	16,707			15,435
Goodwill	336,550			337,751
Intangible assets, net	155,750			168,107
Long-term deferred tax assets	9,451			9,454
Prepaid commissions	38,620			41,432
Other long-term assets	59,655			49,316
Total assets	$	1,026,475		$	1,016,362

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	35,261		$	48,290
Accrued compensation	31,168			27,241
Accrued liabilities	31,721			35,693
Long-term debt, current portion, net	17,708			15,208
Deferred revenues, net	85,776			78,774
Total current liabilities	201,634			205,206
Long-term deferred revenues	8,957			10,623
Long-term deferred tax liabilities	34,788			41,446
Other long-term liabilities	11,394			9,829
Long-term debt, net	181,062			194,917
Total liabilities	437,835			462,021
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued	—			—
Common stock, $0.001 par value, 100,000 shares authorized; 48,346 and 47,577 shares issued; 39,204 and 38,432 shares outstanding, respectively	48			48
Treasury stock at cost, 9,145 shares outstanding	(185,074		)	(185,074		)
Additional paid-in capital	612,576			585,755
Retained earnings	169,033			159,725
Accumulated other comprehensive loss	(7,943		)	(6,113		)
Total stockholders’ equity	588,640			554,341
Total liabilities and stockholders’ equity	$	1,026,475		$	1,016,362

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

OMNICELL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)



	Three months ended June 30,						Six months ended June 30,
	2018			2017			2018			2017
	(In thousands, except per share data)
Revenues:
Product revenues	$	134,636		$	130,205		$	265,295		$	228,996
Services and other revenues	54,037			50,837			105,997			100,599
Total revenues	188,673			181,042			371,292			329,595
Cost of revenues:
Cost of product revenues	75,076			81,738			150,493			145,326
Cost of services and other revenues	24,814			21,172			49,561			43,946
Total cost of revenues	99,890			102,910			200,054			189,272
Gross profit	88,783			78,132			171,238			140,323
Operating expenses:
Research and development	15,512			16,911			32,049			33,714
Selling, general, and administrative	65,937			61,922			131,222			123,862
Total operating expenses	81,449			78,833			163,271			157,576
Income (loss) from operations	7,334			(701		)	7,967			(17,253		)
Interest and other income (expense), net	(896		)	196			(3,625		)	(2,260		)
Income (loss) before provision for income taxes	6,438			(505		)	4,342			(19,513		)
Provision for (benefit from) income taxes	(150		)	(2,385		)	(4,966		)	(11,058		)
Net income (loss)	$	6,588		$	1,880		$	9,308		$	(8,455	)
Net income (loss) per share:
Basic	$	0.17		$	0.05		$	0.24		$	(0.23	)
Diluted	$	0.16		$	0.05		$	0.23		$	(0.23	)
Weighted-average shares outstanding:
Basic	38,970			37,250			38,804			37,046
Diluted	40,000			38,370			39,854			37,046

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

OMNICELL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)



	Three months ended June 30,						Six months ended June 30,
	2018			2017			2018			2017
	(In thousands)
Net income (loss)	$	6,588		$	1,880		$	9,308		$	(8,455	)
Other comprehensive income (loss), net of reclassification adjustments:
Unrealized gains (losses) on interest rate swap contracts	(90		)	(153		)	112			29
Foreign currency translation adjustments	(4,414		)	1,076			(1,942		)	1,999
Other comprehensive income (loss)	(4,504		)	923			(1,830		)	2,028
Comprehensive income (loss)	$	2,084		$	2,803		$	7,478		$	(6,427	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

OMNICELL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)



	Six months ended June 30,
	2018			2017
	(In thousands)
Operating Activities
Net income (loss)	$	9,308		$	(8,455	)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	24,829			25,942
Loss on disposal of fixed assets	—			79
Share-based compensation expense	13,766			11,056
Income tax benefits from employee stock plans	—			11
Deferred income taxes	(6,655		)	(11,722		)
Amortization of debt financing fees	1,145			795
Changes in operating assets and liabilities, net of business acquisitions:
Accounts receivable and unbilled receivables	15,476			(1,058		)
Inventories	(9,789		)	(12,226		)
Prepaid expenses	2,126			128
Other current assets	(2,283		)	202
Investment in sales-type leases	(1,838		)	5,482
Prepaid commissions	2,812			1,554
Other long-term assets	(2,797		)	(622		)
Accounts payable	(12,229		)	23,357
Accrued compensation	3,927			4,529
Accrued liabilities	(2,574		)	2,165
Deferred revenues	5,336			(3,412		)
Other long-term liabilities	167			1,119
Net cash provided by operating activities	40,727			38,924
Investing Activities
Purchases of intangible assets, intellectual property, and patents	—			(160		)
Software development for external use	(13,091		)	(6,748		)
Purchases of property and equipment	(14,985		)	(6,493		)
Business acquisitions, net of cash acquired	—			(4,446		)
Net cash used in investing activities	(28,076		)	(17,847		)
Financing Activities
Proceeds from debt	—			10,000
Repayment of debt and revolving credit facility	(12,500		)	(70,500		)
Proceeds from stock issuances under stock-based compensation plans	16,117			15,783
Employees’ taxes paid related to restricted stock units	(3,062		)	(2,638		)
Net cash provided by (used in) financing activities	555			(47,355		)
Effect of exchange rate changes on cash and cash equivalents	538			(1,274		)
Net increase (decrease) in cash and cash equivalents	13,744			(27,552		)
Cash and cash equivalents at beginning of period	32,424			54,488
Cash and cash equivalents at end of period	$	46,168		$	26,936
Supplemental disclosure of non-cash activities
Unpaid purchases of property and equipment	$	892		$	641
Inventory transferred to property and equipment	$	2,194		$	—
Effect of adoption of ASU No. 2016-09, “Compensation - Stock Compensation (Topic 718)”	$	—		$	1,582

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

OMNICELL, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Note 1. Organization and Summary of Significant Accounting Policies

Business

Omnicell, Inc. was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. The Company’s major products are automated medication, supply control systems and medication adherence solutions which are sold in its principal market, which is the healthcare industry. The Company’s market is primarily located in the United States and Europe. “Omnicell” or the “Company” collectively refer to Omnicell, Inc. and its subsidiaries.

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of the Company as of June 30, 2018 and December 31, 2017, and the results of its operations, comprehensive income (loss), and cash flows for the three and six months ended June 30, 2018 and June 30, 2017. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and accompanying Notes included in the Company’s annual report on Form 10-K for the year ended December 31, 2017 filed with the SEC on February 27, 2018, except as discussed in the section entitled “Revenue Recognition” below. The Company’s results of operations, comprehensive income (loss) and cash flows for the three and six months ended June 30, 2018 are not necessarily indicative of results that may be expected for the year ending December 31, 2018, or for any future period.

Certain prior-year amounts have been adjusted to conform with the adoption of ASC 606, Revenue from Contracts with Customers (“ASC 606”), which became effective for the Company beginning on January 1, 2018. Refer to “Recently Adopted Authoritative Guidance” for the effects of adoption of ASC 606 and the section below for the updated revenue recognition policy.

Certain prior-year amounts have been reclassified to conform with current-period presentation. These reclassifications include (i) reclassification of revenues from services and other revenues to product revenues of $0.2 million and $0.3 million for the three and six months ended June 30, 2017, respectively, related to software term-license sales, (ii) change in inventories presentation related to allocation of inventories obsolete reserve between finished goods, raw materials, and work in progress in the Notes to the Condensed Consolidated Financial Statements, and (iii) change in intangible assets presentation related to presenting foreign currency impact separately in the Notes to the Condensed Consolidated Financial Statements. These changes were not deemed material and were included to conform with current-period classification and presentation.

Principles of Consolidation

The Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Revenue Recognition

The Company earns revenues from sales of its medication and medical and surgical supply automation systems, along with consumables and related services, which are sold in the healthcare industry, its principal market. The transaction price of each contract with a customer is allocated to the identified performance obligations based on the relative fair value of each obligation. The Company’s customer arrangements typically include one or more of the following performance obligations:

Products. Software-enabled equipment that manages and regulates the storage and dispensing of pharmaceuticals, consumable blister cards and packaging equipment and other medical supplies.

Software. Additional software applications that enable incremental functionality of its equipment.

Installation. Installation of equipment as integrated systems at customers’ sites.

Post-installation technical support. Phone support, on-site service, parts, and access to unspecified software updates and enhancements, if and when available.

Table of Contents

Professional services. Other customer services, such as training and consulting.

Prior to recognizing revenue, the Company identifies the contract, performance obligations, and transaction price, and allocates the transaction price to the performance obligations. All identified contracts meet the following required criteria:

Parties to the contract have approved the contract (in writing, orally, or in accordance with other customary business practices) and are committed to perform their respective obligations. A majority of the Company’s contracts are evidenced by a non-cancelable written agreement. Contracts for consumable products are generally evidenced by an order placed via phone or a manual purchase order.

Entity can identify each party’s rights regarding the goods or services to be transferred. Contract terms are documented within the written agreements. Where a written contract does not exist, such as for consumable products, the rights of each party are understood as following the Company’s standard business process and terms.

The entity can identify the payment terms for the goods or services to be transferred. Payment terms are documented within the agreement and are generally net 30 days from shipment of tangible product or services performed. Where a written contract does not exist, the Company’s standard payment terms are net 30 day terms.

The contract has commercial substance (that is the risk, timing, or amount of the entity’s future cash flows is expected to change as a result of the contract.) The Company’s agreements are an exchange of cash for a combination of products and services which result in changes in the amount of the Company’s future cash flows.

It is probable the entity will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. The Company performs a credit check for all significant customers or transactions and where collectability is not probable, payment in full or a substantial down payment is typically required to help assure the full agreed upon contract price will be collected.

The Company often enters into change orders which modify the product to be received by the customer pursuant to certain contracts. Changes to any contract are accounted for as a modification of the existing contract to the extent the goods and services to be delivered as part of the contract are generally consistent with the nature and type of those to be provided under the terms of the original contract. Examples of such change orders include the addition or removal of units of equipment or changes to the configuration of the equipment where the overall nature of the contract remains intact. The Company’s change orders generally result in the change being accounted for as modifications of existing contracts given the nature of the impacted orders.

Distinct goods or services are identified as performance obligations. A series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer are considered a single performance obligation. Where a good or service is determined not to be distinct, the Company combines the good or service with other promised goods or services until a bundle of goods or services that is distinct is identified. To identify its performance obligations, the Company considers all of the products or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. When performance obligations are included in separate contracts, the Company considers an entire customer arrangement to determine if separate contracts should be considered combined for the purposes of revenue recognition. Most of the Company’s sales, other than renewals of support and maintenance, contain multiple performance obligations, with a combination of hardware systems, consumables and software products, support and maintenance, and professional services.

The transaction price of a contract is determined based on the fixed consideration, net of an estimate for variable consideration such as various discounts or rebates provided to customers. As a result of the Company’s commercial selling practices, contract prices are generally fixed with minimal, if any, variable consideration.

The transaction price is allocated to separate performance obligations proportionally based on the standalone selling price of each performance obligation. Standalone selling price is best evidenced by the price the Company charges for the good or service when selling it separately in similar circumstances to similar customers. Other than for the renewal of annual support services contracts, the Company’s products and services are not generally sold separately. The Company uses an expected cost plus a margin approach to identify the standalone selling price of goods where separate sales transactions do not exist. For software and services which do not have a specific identifiable product cost, the Company uses a discounted from the list price amount as a best estimated selling price.

The Company recognizes revenue when the performance obligation has been satisfied by transferring a promised good or service to a customer. The good or service is transferred when or as the customer obtains control of the good or service. Determining when control transfers requires management to make judgments that affect the timing of revenues recognized. Generally, for products requiring a complex implementation, control passes when the product is installed and ready for use. For all other products, control generally passes when product has been shipped and title has passed. For maintenance contracts and

Table of Contents

certain other services provided on a subscription basis, control passes to the customer over time, generally ratably over the service term as the Company provides a stand-ready service to service the customer’s equipment. Time and material services transfer control to the customer at the time the services are provided. The portion of the transaction price allocated to the Company’s unsatisfied performance obligations recorded as deferred revenues at June 30, 2018 and December 31, 2017 was $94.7 million and $89.4 million, respectively, of which $85.8 million and $78.8 million, respectively, are expected to be completed within one year. Remaining performance obligations primarily relate to maintenance contracts and are recognized ratably over the remaining term of the contract, generally not more than five years.

Revenues, contract assets, and contract liabilities are recorded net of associated taxes.

The payment terms associated with the Company’s contracts vary, however, payment terms for product revenues are generally based on milestones tied to contract signing, shipment of products, and/or customer acceptance. Payment terms associated with the service portion of agreements are generally periodic and can be billed on a monthly, quarterly, or annual basis. In certain circumstances multiple years are billed at one time. The portion of these contract liabilities not expected to be recognized as revenue within twelve months of the balance sheet date are considered long term.

In the normal course of business, the Company typically does not accept product returns unless the item is defective as manufactured or the configuration of the product is incorrect. The Company establishes provisions for estimated returns based on historical product returns. The allowance for sales returns is not material to the Condensed Consolidated Financial Statements for any periods presented.

A portion of the Company's sales are made through multi-year lease agreements. Under sales-type leases, the Company recognizes revenue for its hardware and software products net of lease execution costs, such as post-installation product maintenance and technical support, at the net present value of the lease payment stream once its installation obligations have been met. The Company optimizes cash flows by selling a majority of its non-U.S. government leases to third-party leasing finance companies on a non-recourse basis. The Company has no obligation to the leasing company once the lease has been sold. Some of the Company's sales-type leases, mostly those relating to U.S. government hospitals which comprise approximately 42% of the lease receivable balance, are retained in-house. Revenues from sales-type leases of $7.6 million and $10.2 million for the three months ended June 30, 2018 and 2017, respectively, and $17.4 million and $13.4 million for the six months ended June 30, 2018 and 2017, respectively, are included in product revenues in the Condensed Consolidated Statements of Operations. Interest income in these leases is recognized in product revenues using the effective interest method.

A portion of the Company’s sales are made to customers who are members of Group Purchasing Organizations (“GPOs”). GPOs are often owned fully or in part by the Company’s customers, and the Company pays fees to the GPO on completed contracts. The Company considers these fees consideration paid to customers and records them as reductions to revenue. Fees to GPOs were $2.1 million and $1.2 million for the three months ended June 30, 2018 and 2017, respectively, and $4.0 million and $3.3 million for the six months ended June 30, 2018 and 2017, respectively.

Contract Assets and Contract Liabilities

A contract asset is a right to consideration in exchange for goods or services that the Company has transferred to a customer when that right is conditional and is not just subject to the passage of time. A receivable will be recorded on the balance sheet when the Company has unconditional rights to consideration. A contract liability is an obligation to transfer goods or services for which the Company has received consideration, or for which an amount of consideration is due from the customer. Contract liabilities include customer deposits under non-cancelable contracts, and current and non-current deferred revenue balances. The Company’s contract balances are reported in a net contract asset or liability position on a contract-by-contract basis at the end of each reporting period.

Table of Contents

The following table reflects the Company’s contract assets and contract liabilities:



	June 30, 2018		December 31, 2017
	(In thousands)
Short-term unbilled receivables - included in accounts receivable and unbilled receivables	$	6,031	$	4,590
Long-term unbilled receivables - included in other long-term assets	12,150		9,475
Total contract assets	$	18,181	$	14,065

Short-term deferred revenues	$	85,776	$	78,774
Long-term deferred revenues	8,957		10,623
Total contract liabilities	$	94,733	$	89,397

Significant changes in the contract assets and the contract liabilities balances during the period are the result of the issuance of invoices and recognition of deferred revenues in the normal course of business. Unbilled contract assets which were invoiced during the three and six months ended June 30, 2018 as a result of the right to invoice for the transaction consideration becoming unconditional were not material. The contract modifications entered into during the three and six months ended June 30, 2018 did not have a significant impact on the Company’s contract assets or deferred revenues. During the three and six months ended June 30, 2018, the Company recognized revenues of $21.4 million and $68.0 million, respectively, that was included in the corresponding deferred revenue balance as of December 31, 2017.

Contract Costs

The Company has determined that the incentive portions of its sales commission plans require capitalization since these payments are directly related to sales achieved during a time period. These commissions are earned on the basis of the total purchase order value of new product bookings. Since there are not commensurate commissions earned on renewal of the service bookings, the Company concluded that the capitalized asset is related to services provided under both the initial contract and renewal periods. The Company applies a practical expedient to account for the incremental costs of obtaining a contract to a portfolio of contracts with similar characteristics as the Company expects the effect on the financial statements of applying the practical expedient would not differ materially from applying the accounting guidance to the individual contracts within the portfolio. A pool of contracts is defined as all contracts booked in a particular quarter. The amortization for the capitalized asset is an estimate of the pool’s original contract term, generally one to five years, plus an estimate of future customer renewal periods resulting in a total amortization period of ten years. Costs to obtain a contract are allocated amongst performance obligations and recognized as sales and marketing expense consistent with the pattern of revenue recognition. Capitalized costs are periodically reviewed for impairment. A portion of the pool’s capitalized asset is recorded as an expense after two quarters, which represents the estimated period during which the product revenue associated with the contract is recorded. The remaining contract cost is recorded as expense ratably over the ten year estimated initial and renewal service periods. The Company recognized contract cost expense of $5.3 million and $4.6 million during the three months ended June 30, 2018 and 2017, respectively, and $10.9 million and $8.7 million during the six months ended June 30, 2018 and 2017, respectively. The portion of commission expenses paid as of the balance sheet date to be recognized in future periods is recorded in long term prepaid commissions expense on the Condensed Consolidated Balance Sheets. There was no impairment loss in relation to the costs capitalized during the three and six months ended June 30, 2018.

Use of Estimates

The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s Condensed Consolidated Financial Statements and accompanying Notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company’s critical accounting policies are those that affect its financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition; accounts receivable and notes receivable from investment in sales-type leases; inventory valuation; capitalized software development costs; valuation and impairment of goodwill; purchased intangibles and long-lived assets; fair value of assets acquired and liabilities assumed in business combination; share-based compensation; and accounting for income taxes.

Table of Contents

Segment Reporting

The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company’s segments using information about its revenues, gross profit, and income from operations. Such evaluation excludes general corporate-level costs that are not specific to either of the reportable segments and are managed separately at the corporate level. Corporate-level costs include expenses related to executive management; finance and accounting; human resources; legal; training and development; and certain other administrative expenses. See Note 14, Segment and Geographical Information, for additional information on segment reporting.

Recently Adopted Authoritative Guidance

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASC 606, Revenue from Contracts with Customers, a new standard related to revenue recognition. Under the new standard, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenues and cash flows arising from contracts with customers. The guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (modified retrospective method). The Company adopted the standard using the full retrospective method effective beginning January 1, 2018.

Under the ASC 606 guidance, fees paid to GPOs are now presented as a reduction of product revenues, whereas these fees were considered a part of selling, general, and administrative costs under the previous guidance. The majority of the incremental costs incurred to obtain a contract, primarily commission expense, are recognized during the first year with the balance recognized ratably over a period of ten years. Additionally, revenue on term software licenses is recognized upon installation of the license rather than ratably over the life of the term license. Finally, the Company no longer defers the contingent revenue in transactions where the amount charged to the customer for a particular performance obligation is less than the allocation of standalone selling price.

Adoption of the standard related to revenue recognition impacted the Company’s reported results as follows:



	Three months ended June 30, 2017
	As reported			Adjustment			As adjusted
	(In thousands)
Revenues
Automation and Analytics	$	148,427		$	157		$	148,584
Medication Adherence	32,458			—			32,458
Gross profit
Automation and Analytics	67,711			157			67,868
Medication Adherence	10,264			—			10,264
Selling, general, and administrative expenses	63,468			(1,546		)	61,922
Provision for (benefit from) income taxes	(3,045		)	660			(2,385		)
Net income	$	837		$	1,043		$	1,880
Net income per share	$	0.02		$	0.03		$	0.05

Table of Contents



	Six months ended June 30, 2017
	As reported			Adjustment			As adjusted
	(In thousands)
Revenues
Automation and Analytics	$	272,598		$	(1,844	)	$	270,754
Medication Adherence	58,841			—			58,841
Gross profit
Automation and Analytics	123,121			(1,844		)	121,277
Medication Adherence	19,046			—			19,046
Selling, general, and administrative expenses	128,093			(4,231		)	123,862
Provision for (benefit from) income taxes	(11,983		)	925			(11,058		)
Net income (loss)	$	(9,917	)	$	1,462		$	(8,455	)
Net income (loss) per share	$	(0.27	)	$	0.04		$	(0.23	)



	December 31, 2017
	As reported		Adjustment			As adjusted
	(In thousands)
Accounts receivable and unbilled receivables, net	$	189,227	$	819		$	190,046
Prepaid expenses	36,060		(15,668		)	20,392
Prepaid commissions	—		41,432			41,432
Other long-term assets	39,841		9,475			49,316
Deferred revenues, net	86,104		(7,330		)	78,774
Long-term, deferred revenues	17,244		(6,621		)	10,623
Long-term, deferred tax liabilities	28,579		12,867			41,446
Stockholders’ equity	517,199		37,142			554,341

Recently Issued Authoritative Guidance

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The FASB amended lease accounting requirements to begin recording assets and liabilities arising from most leases on the balance sheet. The new guidance will also require significant additional disclosures about the amount and timing of cash flows from leases. This new guidance will be effective for the Company beginning January 1, 2019 using a modified retrospective approach. The modified retrospective approach includes a number of optional practical expedients that entities may elect to apply. The Company is currently evaluating the impact ASU 2016-02 will have on its consolidated financial statements.

In February 2018, the FASB issued ASU 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which permits the reclassification of the income tax effects of the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) on items within accumulated other comprehensive income to retained earnings. These amounts are commonly referred to as “stranded tax effects.” ASU 2018-02 will be effective for the Company beginning January 1, 2019. The Company does not expect application of this guidance to have a material effect on its consolidated financial statements.

There was no other recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s Condensed Consolidated Financial Statements through the reporting date.

Note 2. Business Acquisitions

2017 Acquisitions

On April 12, 2017, the Company completed the acquisition of all of the membership interest of Dixie Drawl, LLC d/b/a InPharmics (“InPharmics”). InPharmics is a technology and services company that provides advanced pharmacy informatics solutions to hospital pharmacies. The total consideration for the transaction was $5.0 million, net of cash acquired of $0.3 million, and includes $0.5 million holdback for potential settlement of performance obligations. At June 30, 2018, this amount has been presented as a short-term liability.

Table of Contents

The Company accounted for the acquisition of InPharmics in accordance with the authoritative guidance on business combinations; therefore, the tangible and intangible assets acquired and liabilities assumed were recorded at fair value on the acquisition date. The purchase price was preliminarily allocated to intangible assets in the amount of $1.9 million, which included developed technology and customer contracts, with the remainder allocated to goodwill.

The results of the InPharmics’ operations have been included in the Company’s consolidated results of operations and are presented as part of the Automation and Analytics segment.

Note 3. Net Income (Loss) Per Share

Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of shares outstanding during the period, less shares repurchased. In periods of net loss, all potential common shares are anti-dilutive, so diluted net loss per share equals the basic net loss per share. In periods of net income, diluted net income per share is computed by dividing net income for the period by the basic weighted-average number of shares plus any dilutive potential common stock outstanding during the period. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards, and restricted stock units computed using the treasury stock method. Any anti-dilutive weighted-average dilutive shares related to stock award plans are excluded from the computation of the diluted net income per share.

The basic and diluted net income (loss) per share calculation for the three and six months ended June 30, 2018 and 2017 was as follows:



	Three months ended June 30,				Six months ended June 30,
	2018		2017		2018		2017
	(In thousands, except per share data)
Net income (loss)	$	6,588	$	1,880	$	9,308	$	(8,455	)
Weighted-average shares outstanding — basic	38,970		37,250		38,804		37,046
Effect of dilutive securities from stock award plans	1,030		1,120		1,050		—
Weighted-average shares outstanding — diluted	$	40,000	$	38,370	39,854		37,046
Net income (loss) per share - basic	$	0.17	$	0.05	$	0.24	$	(0.23	)
Net income (loss) per share - diluted	$	0.16	$	0.05	$	0.23	$	(0.23	)

Anti-dilutive weighted-average shares related to stock award plans	1,264		2,121		1,249		4,039

Note 4. Cash and Cash Equivalents and Fair Value of Financial Instruments

Cash and cash equivalents of $46.2 million and $32.4 million as of June 30, 2018 and December 31, 2017, respectively, consisted of demand deposits only.

Interest Rate Swap Contracts

The Company uses interest rate swap agreements to protect the Company against adverse fluctuations in interest rates by reducing its exposure to variability in cash flows relating to interest payments on a portion of its outstanding debt. The Company’s interest rate swaps, which are designated as cash flow hedges, involve the receipt of variable amounts from counterparties in exchange for the Company making fixed-rate payments over the life of the agreements. The Company does not hold or issue any derivative financial instruments for speculative trading purposes.

During 2016, the Company entered into an interest rate swap agreement with a combined notional amount of $100.0 million with one counterparty that became effective on June 30, 2016 and is maturing on April 30, 2019. The swap agreement requires the Company to pay a fixed rate of 0.8% and provides that the Company will receive a variable rate based on the one month LIBOR rate subject to a LIBOR floor of 0.0%. Amounts payable by or due to the Company will be net settled with the respective counterparty on the last business day of each month, commencing July 31, 2016.

The fair value of the interest rate swap agreements at June 30, 2018 and December 31, 2017 was $1.3 million and $1.4 million, respectively. There were no amounts reclassified into current earnings due to ineffectiveness during the periods presented.

Table of Contents

Fair Value Hierarchy

The Company measures its financial instruments at fair value. The Company’s cash equivalents are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company’s interest rate swap contracts and foreign currency contracts are classified within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments.

The following table represents the fair value hierarchy of the Company’s financial assets and financial liabilities measured at fair value as of June 30, 2018:



	Level 1		Level 2		Level 3		Total
	(In thousands)
Interest rate swap contracts	$	—	$	1,270	$	—	$	1,270
Total financial assets	$	—	$	1,270	$	—	$	1,270

There were no transfers between fair value measurement levels during the six months ended June 30, 2018 and 2017.

The following table represents the fair value hierarchy of the Company’s financial assets and financial liabilities measured at fair value as of December 31, 2017:



	Level 1		Level 2		Level 3		Total
	(In thousands)
Interest rate swap contracts	$	—	$	1,378	$	—	$	1,378
Total financial assets	$	—	$	1,378	$	—	$	1,378

Net Investment in Sales-Type Leases. The carrying amount of the Company’s sales-type lease receivables is a reasonable estimate of fair value, as the unearned interest income is immaterial.

Note 5. Balance Sheet Components

Balance sheet details as of June 30, 2018 and December 31, 2017 are presented in the tables below:



	June 30, 2018			December 31, 2017
	(In thousands)
Inventories:
Raw materials	$	32,046		$	31,275
Work in process	13,028			8,718
Finished goods	58,658			56,144
Total inventories	$	103,732		$	96,137

Property and equipment:
Equipment	$	75,205		$	69,550
Furniture and fixtures	6,779			6,534
Leasehold improvements	15,598			10,976
Software	39,502			37,168
Construction in progress	12,493			9,813
Property and equipment, gross	149,577			134,041
Accumulated depreciation and amortization	(98,693		)	(91,446		)
Total property and equipment, net	$	50,884		$	42,595

Table of Contents



	June 30, 2018		December 31, 2017
Other long term assets:
Capitalized software, net	$	46,141	$	38,599
Unbilled receivables	12,150		9,475
Other assets	1,364		1,242
Total other long term assets, net	$	59,655	$	49,316

Accrued liabilities:
Advance payments from customers	$	7,140	$	7,779
Rebates and lease buyouts	5,195		5,428
Group purchasing organization fees	3,677		3,449
Taxes payable	6,067		9,183
Other accrued liabilities	9,642		9,854
Total accrued liabilities	$	31,721	$	35,693

The following table summarizes the changes in accumulated balances of other comprehensive income (loss) for the three and six months ended June 30, 2018 and 2017:



	Three months ended June 30,
	2018									2017
	Foreign currency translation adjustments			Unrealized gain (loss) on interest rate swap hedges			Total			Foreign currency translation adjustments			Unrealized gain (loss) on interest rate swap hedges			Total
	(In thousands)
Beginning balance	$	(4,482	)	$	1,043		$	(3,439	)	$	(9,841	)	$	1,427		$	(8,414	)
Other comprehensive income (loss) before reclassifications	(4,414		)	195			(4,219		)	1,076			(100		)	976
Amounts reclassified from other comprehensive income (loss), net of tax	—			(285		)	(285		)	—			(53		)	(53		)
Net current-period other comprehensive income (loss), net of tax	(4,414		)	(90		)	(4,504		)	1,076			(153		)	923
Ending balance	$	(8,896	)	$	953		$	(7,943	)	$	(8,765	)	$	1,274		$	(7,491	)




	Six months ended June 30,
	2018									2017
	Foreign currency translation adjustments			Unrealized gain (loss) on interest rate swap hedges			Total			Foreign currency translation adjustments			Unrealized gain (loss) on interest rate swap hedges			Total
	(In thousands)
Beginning balance	$	(6,954	)	$	841		$	(6,113	)	$	(10,764	)	$	1,245		$	(9,519	)
Other comprehensive income (loss) before reclassifications	(1,942		)	596			(1,346		)	1,999			76			2,075
Amounts reclassified from other comprehensive income (loss), net of tax	—			(484		)	(484		)	—			(47		)	(47		)
Net current-period other comprehensive income (loss), net of tax	(1,942		)	112			(1,830		)	1,999			29			2,028
Ending balance	$	(8,896	)	$	953		$	(7,943	)	$	(8,765	)	$	1,274		$	(7,491	)

Table of Contents

Note 6. Net Investment in Sales-Type Leases

On a recurring basis, the Company enters into sales-type lease transactions with the majority varying in length from one to five years. The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components at June 30, 2018 and December 31, 2017:



	June 30, 2018			December 31, 2017
	(In thousands)
Net minimum lease payments to be received	$	27,303		$	25,899
Less: Unearned interest income portion	(2,141		)	(1,695		)
Net investment in sales-type leases	25,162			24,204
Less: Short-term portion⁽¹⁾	(8,455		)	(8,769		)
Long-term net investment in sales-type leases	$	16,707		$	15,435

_________________________________________________


⁽¹⁾	The short-term portion of the net investments in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets.

The Company evaluates its sales-type leases individually and collectively for impairment. The allowance for credit losses was $0.2 million as of June 30, 2018 and December 31, 2017, respectively.

At June 30, 2018, the future minimum lease payments under sales-type leases were as follows:



	June 30, 2018
	(In thousands)
Remaining six months of 2018	$	5,259
2019	7,635
2020	5,765
2021	3,944
2022	3,299
Thereafter	1,401
Total	$	27,303

Note 7. Goodwill and Intangible Assets

Goodwill

The following table represents changes in the carrying amount of goodwill:



	Automation and Analytics			Medication Adherence			Total
	(In thousands)
Net balance as of December 31, 2017	$	220,851		$	116,900		$	337,751
Foreign currency exchange rate fluctuations	(881		)	(320		)	(1,201		)
Net balance as of June 30, 2018	$	219,970		$	116,580		$	336,550

Table of Contents

Intangible Assets, Net

The carrying amounts of intangible assets as of June 30, 2018 and December 31, 2017 were as follows:



	June 30, 2018
	Gross carrying amount		Accumulated amortization			Foreign currency exchange rate fluctuations			Net carrying amount		Useful life (years)
	(In thousands, except for years)
Customer relationships	$	135,234	$	(39,709	)	$	(1,034	)	$	94,491	1 - 30
Acquired technology	74,222		(25,152		)	125			49,195		3 - 20
Backlog	21,350		(18,943		)	—			2,407		1 - 4
Trade names	7,650		(4,025		)	22			3,647		1 - 12
Patents	3,239		(1,434		)	5			1,810		2 - 20
Non-compete agreements	1,900		(1,600		)	—			300		3
In-process technology	3,900		—			—			3,900		—
Total intangibles assets, net	$	247,495	$	(90,863	)	$	(882	)	$	155,750



	December 31, 2017
	Gross carrying amount		Accumulated amortization			Foreign currency exchange rate fluctuations			Net carrying amount		Useful life (years)
	(In thousands, except for years)
Customer relationships	$	135,234	$	(33,988	)	$	(787	)	$	100,459	1 - 30
Acquired technology	74,222		(21,345		)	221			53,098		3 - 20
Backlog	21,350		(17,182		)	—			4,168		1 - 4
Trade names	7,650		(3,688		)	40			4,002		1 - 12
Patents	3,239		(1,369		)	10			1,880		2 - 20
Non-compete agreements	1,900		(1,300		)	—			600		3
In-process technology	3,900		—			—			3,900		—
Total intangibles assets, net	$	247,495	$	(78,872	)	$	(516	)	$	168,107

Amortization expense of intangible assets was $6.0 million and $6.8 million for the three months ended June 30, 2018 and 2017, respectively. Amortization expense of intangible assets was $12.0 million and $13.0 million for the six months ended June 30, 2018 and 2017, respectively.

The estimated future amortization expenses for amortizable intangible assets were as follows:



	June 30, 2018
	(In thousands)
Remaining six months of 2018	$	11,479
2019	17,949
2020	16,746
2021	15,320
2022	13,968
Thereafter (excluding in-process technology)	76,388
Total	$	151,850

Table of Contents

Note 8. Debt

On January 5, 2016, the Company entered into a $400.0 million senior secured credit facility pursuant to a credit agreement with certain lenders, Wells Fargo Securities, LLC as sole lead arranger, and Wells Fargo Bank, National Association as administrative agent (the “Credit Agreement”). The Credit Agreement provides for (a) a five-year revolving credit facility of $200.0 million, which was subsequently increased pursuant to the amendment discussed below (the “Revolving Credit Facility”) and (b) a five-year $200.0 million term loan facility (the “Term Loan Facility” and together with the Revolving Credit Facility, the “Facilities”). In addition, the Credit Agreement includes a letter of credit sub-limit of up to $10.0 million and a swing line loan sub-limit of up to $10.0 million. The Credit Agreement expires on January 5, 2021, upon which date all remaining outstanding borrowings are due and payable.

Loans under the Facilities bear interest, at the Company’s option, at a rate equal to either (a) the LIBOR Rate, plus an applicable margin ranging from 1.50% to 2.25% per annum based on the Company’s consolidated total net leverage ratio (as defined in the Credit Agreement), or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50%, and (iii) LIBOR for an interest period of one month, plus an applicable margin ranging from 0.50% to 1.25% per annum based on the Company’s consolidated total net leverage ratio (as defined in the Credit Agreement). Undrawn commitments under the Revolving Credit Facility will be subject to a commitment fee ranging from 0.20% to 0.35% per annum based on the Company’s consolidated total net leverage ratio on the average daily unused portion of the Revolving Credit Facility. A letter of credit participation fee ranging from 1.50% to 2.25% per annum based on the Company’s consolidated total net leverage ratio will accrue on the average daily amount of letter of credit exposure.

The Company is permitted to make voluntary prepayments at any time without payment of a premium or penalty, except for any amounts relating to the LIBOR breakage indemnity described in the Credit Agreement. The Company is required to make mandatory prepayments under the Term Loan Facility with (a) net cash proceeds from any issuances of debt (other than certain permitted debt) and (b) net cash proceeds from certain asset dispositions (other than certain asset dispositions) and insurance and condemnation events (subject to reinvestment rights and certain other exceptions). Loans under the Term Loan Facility will amortize in quarterly installments, equal to 5% per annum of the original principal amount thereof during the first two years, which shall increase to 10% per annum during the third and fourth years, and 15% per annum during the fifth year, with the remaining balance payable on January 5, 2021. The Company is required to make mandatory prepayments under the Revolving Credit Facility if at any time the aggregate outstanding principal amount of loans together with the total amount of outstanding letters of credit exceeds the aggregate commitments, with such mandatory prepayment to be equal to the amount of such excess.

The Credit Agreement contains customary representations and warranties, and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends, and other distributions. The Credit Agreement contains financial covenants that require the Company and its subsidiaries to not exceed a maximum consolidated total leverage ratio and maintain a minimum fixed charge coverage ratio. The Company’s obligations under the Credit Agreement, and any swap obligations and banking services obligations owing to a lender (or an affiliate of a lender), are guaranteed by certain of its domestic subsidiaries and secured by substantially all of its and the subsidiary guarantors’ assets. In connection with entering into the Credit Agreement, and as a condition precedent to borrowing loans thereunder, the Company and certain of the Company’s other direct and indirect subsidiaries have entered into certain ancillary agreements, including, but not limited to, a collateral agreement and subsidiary guaranty agreement.

On April 11, 2017, the parties entered into the First Amendment to Credit Agreement and Collateral Agreement (the “Amended Credit Agreement”). Under this amendment, (i) the maximum capital expenditures limit in any fiscal year for property, plant, and equipment and software development increased from $35.0 million to $45.0 million, and (ii) the maximum limit for non-permitted investments increased from $10.0 million to $20.0 million.

On December 26, 2017, the parties entered into another amendment (the “Amendment”) to the Amended Credit Agreement. Pursuant to the Amendment, the Revolving Credit Facility provided for under the Amended Credit Agreement, was increased from $200.0 million to $315.0 million, and certain other modifications to the Amended Credit Agreement were made, including amendments to certain negative covenants.

In connection with these Facilities, the Company incurred $10.1 million of debt issuance costs. The debt issuance costs were capitalized and presented as a direct deduction from the carrying amount of that debt liability in accordance with the accounting guidance. The debt issuance costs are being amortized to interest expense using the straight line method from issuance date through 2021. Interest expense (exclusive of fees and issuance cost amortization) was approximately $1.9 million and $1.5 million for the three months ended June 30, 2018 and 2017, respectively, and approximately $3.8 million and $3.0 million for the six months ended June 30, 2018 and 2017, respectively. Amortization expense related to fees and issuance cost was approximately $0.6 million and $0.4 million for the three months ended June 30, 2018 and 2017, respectively, and

Table of Contents

approximately $1.1 million and $0.8 million for the six months ended June 30, 2018 and 2017, respectively. The Company was in compliance with all covenants as of June 30, 2018 and December 31, 2017.

During the six months ended June 30, 2018, the Company repaid $12.5 million under these Facilities.

The components of the Company’s debt obligations as of June 30, 2018 and December 31, 2017 were as follows:



	December 31, 2017			Borrowings		Repayment / Amortization			June 30, 2018
	(In thousands)
Term loan facility	$	182,500		$	—	$	(7,500	)	$	175,000
Revolving credit facility	34,500			—		(5,000		)	29,500
Total debt under the facilities	217,000			—		(12,500		)	204,500
Less: Deferred issuance cost	(6,875		)	—		1,145			(5,730		)
Total debt, net of deferred issuance cost	$	210,125		$	—	$	(11,355	)	$	198,770
Long term debt, current portion, net of deferred issuance cost	15,208								17,708
Long term debt, net of deferred issuance cost	$	194,917							$	181,062

As of June 30, 2018, the carrying amount of debt of $204.5 million approximates the comparable fair value of $207.4 million. The Company’s debt facilities are classified as a Level 3 in the fair value hierarchy. The calculation of the fair value is based on a discounted cash flow model using observable market inputs and taking into consideration variables such as interest rate changes, comparable instruments and long-term credit ratings. There have been no significant changes in the assumptions used as of June 30, 2018 as compared to the period as of December 31, 2017.

Note 9. Deferred Revenues

Short-term deferred revenues of $85.8 million and $78.8 million include deferred revenues from product sales and service contracts, net of deferred cost of sales of $14.6 million and $16.9 million as of June 30, 2018 and December 31, 2017, respectively. The short-term deferred revenues from product sales relate to delivered and invoiced products, pending installation and acceptance, expected to occur within the next twelve months.

Long-term deferred revenues include deferred revenues from service contracts of $9.0 million and $10.6 million, as of June 30, 2018 and December 31, 2017, respectively.

Note 10. Commitments and Contingencies

Lease Commitments

The Company leases office space and office equipment under operating leases. Commitments under operating leases primarily relate to leasehold property and office equipment. At June 30, 2018, the minimum future payments on non-cancelable operating leases were as follows:



	(In thousands)
Remaining six months of 2018	$	6,651
2019	13,264
2020	11,399
2021	10,465
2022	8,660
Thereafter	26,707
Total minimum future lease payments	$	77,146

Purchase Obligations

In the ordinary course of business, the Company issues purchase orders based on its current manufacturing needs. At June 30, 2018, the Company had non-cancelable purchase commitments of $56.2 million, which are expected to be paid within the next twelve months.

Table of Contents

Legal Proceedings

The Company is currently involved in various legal proceedings. As required under ASC 450, Contingencies, the Company accrues for contingencies when it believes that a loss is probable and that it can reasonably estimate the amount of any such loss. The Company has not recorded any accrual for contingent liabilities associated with the legal proceedings described below based on its belief that any potential loss, while reasonably possible, is not probable. Further, any possible range of loss in these matters cannot be reasonably estimated at this time. The Company believes that it has valid defenses with respect to legal proceedings pending against it. However, litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of this contingency or because of the diversion of management’s attention and the creation of significant expenses.

On January 10, 2018, a lawsuit was filed against a number of individuals, governmental agencies, and corporate entities, including the Company and one of its subsidiaries, Aesynt Incorporated (“Aesynt”), in the Circuit Court for the City of Richmond, Virginia, captioned Ruth Ann Warner, as Guardian of Jonathan James Brewster Warner v. Centra Health, Inc., et al., Case No. CL18-152-1. The complaint seeks monetary recovery of compensatory and punitive damages in addition to certain declaratory relief based upon, as against the individuals, governmental agencies, and corporate entities other than the Company and Aesynt, allegations of the use of excessive force, unlawful detention, false imprisonment, battery, simple and gross negligence and negligent hiring, detention, and training; and, as against the Company and Aesynt, claims of product liability, negligence, and breach of implied warranties. The Company and Aesynt have not yet been served with the complaint. The Company intends to defend the lawsuit vigorously.

On June 6, 2018, a class-action lawsuit was filed against a customer of the Company, the customer’s parent company and two vendors of medication dispensing systems, one of which is the Company, in the Circuit Court of Cook County, Illinois, Chancery Division, captioned Yana Mazya, individually and on behalf of all others similarly situated v. Northwestern Lake Forest Hospital, Northwestern Memorial Healthcare, Omnicell, Inc. and Becton Dickinson, Case No. 2018-CH-07161. The complaint seeks class certification, monetary damages in the form of statutory damages for willful and/or reckless or, in the alternative, negligent violation of the Illinois Biometric Information Privacy Act (“BIPA”), and certain declaratory, injunctive, and other relief based on causes of action directed to allegations of violation of BIPA and of negligence by the defendants. The complaint was served on the Company on June 15, 2018. Counsel for the proposed class filed a motion to certify the class; the court continued the motion and scheduled a status conference for October 4, 2018. The Company’s obligation to respond to the complaint has been held in abeyance until further determination by the court. The Company intends to defend the lawsuit vigorously.

Note 11. Income Taxes

On December 22, 2017, the Tax Act was signed into law, most provisions of which became effective starting in 2018, including the reduction of the statutory corporate income tax rate from 35% to 21%. As of June 30, 2018, the Company has not completed the accounting for the tax effects of enactment of the Tax Act; however, in the fourth quarter of 2017, the Company made a reasonable estimate of the effects on the existing deferred tax balances and the one-time transition tax. No adjustments to the provisional amounts recorded in the fourth quarter of 2017 were made during the three and six months ended June 30, 2018, respectively. For the six months ended June 30, 2018, the Company assessed the effect of certain international provisions of the Tax Act that became effective January 1, 2018, and determined that these provisions had an immaterial impact; therefore, the Company did not record any impact as a result of the assessment. The Company will continue to analyze the provision for income taxes under the Tax Act as future guidance is issued. Any revisions will be treated in accordance with the measurement period guidance outlined in SEC Staff Accounting Bulletin No. 118.

The Company generally provides for income taxes in interim periods based on the estimated annual effective tax rate for the year, adjusting for discrete items in the quarter in which they arise. The annual effective tax rate before discrete items was 16.5% and 41.1% for the six months ended June 30, 2018 and 2017, respectively.

The 2018 annual effective tax rate differed from the statutory rate of 21% primarily due to the favorable impact of the research and development credits and foreign rate differential, which were partially offset by the unfavorable impact of state income taxes, non-deductible expenses, and non-deductible equity charges. The 2017 annual effective tax rate differed from the statutory rate of 35% primarily due to the unfavorable impact of state income taxes, foreign rate differential, and non-deductible equity charges, which were partially offset by the domestic production activities deduction and the research and development credits.

As of June 30, 2018 and December 31, 2017, the Company had gross unrecognized tax benefits of $11.6 million and $10.7 million, respectively. It is the Company’s policy to classify accrued interest and penalties as part of the unrecognized tax benefits, but to record interest and penalties in operating expense. As of June 30, 2018 and December 31, 2017, the amount of accrued interest and penalties was $1.7 million and $1.4 million, respectively.

Table of Contents

The Company files income tax returns in the United States and various states and foreign jurisdictions. In the normal course of business, the Company is subject to examination by taxing authorities, including major jurisdictions such as the United States, Germany, Italy, Netherlands, and the United Kingdom. With few exceptions, as of June 30, 2018, the Company is no longer subject to U.S., state, and foreign examination for years before 2014, 2013, and 2014, respectively.

Although the Company believes it has adequately provided for uncertain tax positions, the provisions on these positions may change as revised estimates are made or the underlying matters are settled or otherwise resolved. It is not possible at this time to reasonably estimate changes in the unrecognized tax benefits within the next twelve months.

Note 12. Employee Benefits and Share-Based Compensation

Stock-Based Plans

For a detailed explanation of the Company's stock plans and subsequent changes, please refer to Note 11, Employee Benefits and Share-Based Compensation, of the Company's annual report on Form 10-K for the year ended December 31, 2017 filed with the SEC on February 27, 2018.

Share-Based Compensation Expense

The following table sets forth the total share-based compensation expense recognized in the Company’s Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2018 and 2017:



	Three months ended				Six months ended
	June 30, 2018		June 30, 2017		June 30, 2018		June 30, 2017
	(In thousands)
Cost of product and service revenues	$	1,177	$	845	$	2,196	$	1,827
Research and development	1,437		810		2,671		1,707
Selling, general, and administrative	4,624		3,890		8,899		7,522
Total share-based compensation expense	$	7,238	$	5,545	$	13,766	$	11,056

Stock Options and ESPP Shares

The following assumptions were used to value share options and Employee Stock Purchase Plan (“ESPP”) shares granted pursuant to the Company’s equity incentive plans for the three and six months ended June 30, 2018 and 2017:



	Three months ended				Six months ended
	June 30, 2018		June 30, 2017		June 30, 2018		June 30, 2017
Stock option plans
Expected life, years	4.8		4.7		4.8		4.7
Expected volatility, %	30.6	%	28.3	%	31.4	%	29.7	%
Risk free interest rate, %	2.8	%	1.8	%	2.7	%	1.8	%
Estimated forfeiture rate, %	6.9	%	7.7	%	6.9	%	7.7	%
Dividend yield, %	—	%	—	%	—	%	—	%



	Three months ended				Six months ended
	June 30, 2018		June 30, 2017		June 30, 2018		June 30, 2017
Employee stock purchase plan
Expected life, years	0.5-2.0		0.5-2.0		0.5-2.0		0.5-2.0
Expected volatility, %	27.7-33.8%		25.8-32.8%		27.7-33.8%		25.8-32.8%
Risk free interest rate, %	0.7-2.3%		0.5-1.3%		0.7-2.3%		0.5-1.3%
Dividend yield, %	—	%	—	%	—	%	—	%

Table of Contents

Stock Options Activity

The following table summarizes the share option activity under the Company’s equity incentive plans during the six months ended June 30, 2018:



	Number of Shares		Weighted-Average Exercise Price		Weighted-Average Remaining Years	Aggregate Intrinsic Value
	(In thousands, except per share data)
Stock options
Outstanding at December 31, 2017	3,323		$	32.72	7.6	$	53,953
Granted	720		44.73
Exercised	(356	)	24.15
Expired	(6	)	21.92
Forfeited	(172	)	38.13
Outstanding at June 30, 2018	3,509		$	35.80	7.6	$	58,487
Exercisable at June 30, 2018	1,338		$	26.29	5.6	$	35,014
Vested and expected to vest at June 30, 2018 and thereafter	3,303		$	35.34	7.5	$	56,583

The weighted-average fair value per share of options granted during the three months ended June 30, 2018 and 2017 was $14.43 and $11.31, respectively, and the weighted-average fair value per share of options granted during the six months ended June 30, 2018 and 2017 was $14.29 and $10.92, respectively. The intrinsic value of options exercised during the three months ended June 30, 2018 and 2017 was $6.5 million and $4.9 million, respectively, and the intrinsic value of options exercised during the six months ended June 30, 2018 and 2017 was $8.5 million and $7.8 million, respectively.

As of June 30, 2018, total unrecognized compensation cost related to unvested stock options was $23.7 million, which is expected to be recognized over a weighted-average vesting period of 2.9 years.

Employee Stock Purchase Plan Activity

For the six months ending June 30, 2018 and 2017, employees purchased approximately 289,000 and 259,000 shares of common stock, respectively, under the ESPP at weighted average prices of $26.30 and $25.51, respectively. As of June 30, 2018, the unrecognized compensation cost related to the shares to be purchased under the ESPP was approximately $4.7 million and is expected to be recognized over a weighted-average period of 1.2 years.

Restricted Stock Units and Restricted Stock Awards

Summaries of restricted stock activity under the Company’s 2009 Equity Incentive Plan, as amended (the “2009 Plan”) are presented below for the six months ended June 30, 2018:



	Number of Shares		Weighted-Average Grant Date Fair Value		Weighted-Average Remaining Years	Aggregate Intrinsic Value
	(In thousands, except per share data)
Restricted stock units (“RSUs”)
Outstanding at December 31, 2017	501		$	38.90	1.5	$	24,293
Granted	113		44.38
Vested	(104	)	34.42
Forfeited	(44	)	38.33
Outstanding and unvested at June 30, 2018	466		$	41.28	1.5	$	24,423

As of June 30, 2018, total unrecognized compensation expense related to RSUs was $16.9 million, which is expected to be recognized over the remaining weighted-average vesting period of 2.8 years.

Table of Contents



	Number of Shares		Weighted-Average Grant Date Fair Value
	(In thousands, except per share data)
Restricted stock awards (“RSAs”)
Outstanding at December 31, 2017	23		$	41.07
Granted	21		46.60
Vested	(23	)	41.07
Forfeited	—		—
Outstanding and unvested at June 30, 2018	21		$	46.60

As of June 30, 2018, total unrecognized compensation cost related to RSAs was $0.8 million, which is expected to be recognized over the remaining weighted-average vesting period of 0.9 years.

Performance-Based Restricted Stock Units

A summary of the performance-based restricted stock activity under the 2009 Plan during the six months ended June 30, 2018 is presented below:



	Number of Shares		Weighted-Average Grant Date Fair Value Per Unit
	(In thousands, except per share data)
Performance-based restricted stock units (“PSUs”)
Outstanding at December 31, 2017	225		$	31.18
Granted	110		38.03
Vested	(67	)	30.46
Forfeited	(32	)	34.47
Outstanding and unvested at June 30, 2018	236		$	34.13

As of June 30, 2018, total unrecognized compensation cost related to PSUs was $4.3 million, which is expected to be recognized over the remaining weighted-average period of 1.5 years.

Summary of Shares Reserved for Future Issuance under Equity Incentive Plans

The Company had the following ordinary shares reserved for future issuance under its equity incentive plans as of June 30, 2018:



	Number of Shares
	(In thousands)
Share options outstanding	3,509
Non-vested restricted share awards	723
Shares authorized for future issuance	3,306
ESPP shares available for future issuance	2,077
Total shares reserved for future issuance	9,615

Stock Repurchase Program

On August 2, 2016, the Company's Board of Directors (the “Board”) authorized a stock repurchase program providing for the repurchase of up to $50.0 million of the Company’s common stock (the “2016 Repurchase Program”). The 2016 Repurchase Program is in addition to the stock repurchase program approved by the Board on November 4, 2014 (the “2014 Repurchase Program”). As of June 30, 2018, the maximum dollar value of shares that may yet be purchased under the two repurchase programs was $54.9 million. The stock repurchase programs do not obligate the Company to repurchase any specific number of shares, and the Company may terminate or suspend the repurchase program at any time.

Table of Contents

During the three and six months ended June 30, 2018 and 2017, the Company did not repurchase any of its outstanding common stock.

Note 13. Equity Offerings

On November 3, 2017, the Company entered into a Distribution Agreement (the “Distribution Agreement”) with J.P. Morgan Securities LLC, Wells Fargo Securities, LLC, and HSBC Securities (USA) Inc., as its sales agents, pursuant to which the Company may offer and sell from time to time through the sales agents up to $125.0 million maximum aggregate offering price of the Company’s common stock. Sales of the common stock pursuant to the Distribution Agreement may be made in negotiated transactions or transactions that are deemed to be “at the market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on the Nasdaq Stock Market, or sales made to or through a market maker other than on an exchange.

During the three and six months ended June 30, 2018, the Company did not sell any of its common stock under the Distribution Agreement. As of June 30, 2018, the Company had an aggregate of $110.3 million available to be offered under the Distribution Agreement.

Note 14. Segment and Geographical Information

The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company’s segments using information about its revenues, gross profit, and income from operations. Such evaluation excludes general corporate-level costs that are not specific to either of the reportable segments and are managed separately at the corporate level. Corporate-level costs include expenses related to executive management, finance and accounting, human resources, legal, training and development, and certain administrative expenses.

The two operating segments, which are the same as the Company’s two reportable segments, are as follows:

•

Automation and Analytics. The Automation and Analytics segment is organized around the design, manufacturing, selling, and servicing of medication and supply dispensing systems; pharmacy inventory management systems; and related software. The Automation and Analytics products are designed to enable the Company’s customers to enhance and improve the effectiveness of the medication-use process, the efficiency of the medical-surgical supply chain, overall patient care, and clinical and financial outcomes of medical facilities. Through modular configuration and upgrades, the Company’s systems can be tailored to specific customer needs. The financial results of InPharmics acquired in the second quarter of 2017 are included in the Automation and Analytics segment.

•

Medication Adherence. The Medication Adherence segment includes solutions to assist patients to remain adherent to their medication regimens. These solutions are comprised of a variety of tools and aids that may be directly used by a pharmacist or a healthcare provider in their direct care for a patient, or the patient themselves, and include software-based systems and medication adherence packaging. Software solutions primarily operate on the Patient Management Access Portal (“PMAP”), a subscription-based software system which provides an environment for patient engagement by clinicians. Services running on PMAP include Time My Meds^® medication synchronization, immunization management, and a number of tools used by clinicians to manage patient engagement workflows. Medication Adherence packaging is designed either for patient use in care environments where there is a caregiver present or for environments where the patient cares for him or herself and includes the manufacturing and selling of consumable medication blister cards, packaging equipment, and ancillary products and services.

Table of Contents

The following tables summarize the financial performance of the Company’s reportable segments, including a reconciliation of income from segment operations to income from total operations:



	Three months ended June 30,
	2018							2017
	Automation and Analytics		Medication Adherence			Total		Automation and Analytics		Medication Adherence		Total
	(In thousands)
Revenues:
Product revenues	$	110,262	$	24,374		$	134,636	$	103,557	$	26,648	$	130,205
Services and other revenues	48,103		5,934			54,037		45,027		5,810		50,837
Total revenues	158,365		30,308			188,673		148,584		32,458		181,042
Cost of revenues:
Cost of product revenues	57,045		18,031			75,076		62,185		19,553		81,738
Cost of services and other revenues	21,641		3,173			24,814		18,531		2,641		21,172
Total cost of revenues	78,686		21,204			99,890		80,716		22,194		102,910
Gross profit	79,679		9,104			88,783		67,868		10,264		78,132
Operating expenses	48,167		10,296			58,463		47,508		10,099		57,607
Income from operations	$	31,512	$	(1,192	)	$	30,320	$	20,360	$	165	$	20,525
Corporate costs						22,986						21,226
Income from operations						$	7,334					$	(701	)




	Six months ended June 30,
	2018							2017
	Automation and Analytics		Medication Adherence			Total		Automation and Analytics		Medication Adherence			Total
	(In thousands)
Revenues:
Product revenues	$	215,193	$	50,102		$	265,295	$	182,095	$	46,901		$	228,996
Services and other revenues	94,578		11,419			105,997		88,659		11,940			100,599
Total revenues	309,771		61,521			371,292		270,754		58,841			329,595
Cost of revenues:
Cost of product revenues	113,548		36,945			150,493		111,164		34,162			145,326
Cost of services and other revenues	43,380		6,181			49,561		38,313		5,633			43,946
Total cost of revenues	156,928		43,126			200,054		149,477		39,795			189,272
Gross profit	152,843		18,395			171,238		121,277		19,046			140,323
Operating expenses	96,558		20,495			117,053		95,570		21,295			116,865
Income (loss) from segment operations	$	56,285	$	(2,100	)	$	54,185	$	25,707	$	(2,249	)	$	23,458
Corporate costs						46,218							40,711
Income (loss) from operations						$	7,967						$	(17,253	)

Significant Customers

There were no customers that accounted for more than 10% of the Company’s total revenues for the three and six months ended June 30, 2018 and 2017. Also, there were no customers that accounted for more than 10% of the Company’s accounts receivable as of June 30, 2018 and December 31, 2017.

Table of Contents

Geographical Information

Revenues



	Three months ended June 30,
	2018		2017
	(In thousands)
United States	$	163,645	$	153,442
Rest of world ⁽¹⁾	25,028		27,600
Total revenues	$	188,673	$	181,042




	Six months ended June 30,
	2018		2017
	(In thousands)
United States	$	321,847	$	283,721
Rest of world ⁽¹⁾	49,445		45,874
Total revenues	$	371,292	$	329,595

_________________________________________________

⁽¹⁾No individual country represented more than 10% of the respective totals.

Property and Equipment, Net



	June 30, 2018		December 31, 2017
	(In thousands)
United States	$	43,490	$	34,899
Rest of world ⁽¹⁾	7,394		7,696
Total property and equipment, net	$	50,884	$	42,595

_________________________________________________


⁽¹⁾	No individual country represented more than 10% of the respective totals.

Property and equipment, net is attributed to the geographic location in which it is located.

Note 15. Restructuring Expenses

On March 2, 2018, the Company initiated the realignment of its Automation and Analytics commercial group in North America and France. During the six months ended June 30, 2018, the Company accrued $3.0 million of employee severance cost and related expenses, and paid out $1.9 million. The remaining, unpaid balance of $1.1 million of accrued employee severance cost and related expenses as of June 30, 2018 is presented as a component of accrued compensation liabilities in the Condensed Consolidated Balance Sheets, and is expected to be paid during the third quarter of fiscal year 2018.

On February 15, 2017, the Company announced its plan to reduce its workforce by approximately 100 full-time employees and close the Company’s Nashville, Tennessee and Slovenia facilities. The plan was completed in fiscal year 2017. During the six months ended June 30, 2017, the Company accrued $3.8 million of employee severance cost and related expenses, and paid out $3.1 million. The remaining, unpaid balance of $0.7 million accrued severance cost and related expenses as of June 30, 2017 is presented as a component of accrued compensation in the Condensed Consolidated Balance Sheets. There were $0.6 million of facility-related costs incurred during the six months ended June 30, 2017, of which $0.1 million was paid out. The remaining unpaid balance of $0.5 million accrued facilities-related expenses as of June 30, 2017 is presented as a component of accrued liabilities in the Condensed Consolidated Balance Sheets.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FORWARD-LOOKING STATEMENTS AND FACTORS THAT MAY AFFECT FUTURE RESULTS

This quarterly report on Form 10-Q contains forward-looking statements. The forward-looking statements are contained principally in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements include, but are not limited to, statements about:


•	our expectations regarding our future product bookings;


•	the extent and timing of future revenues, including the amounts of our current backlog;


•	the size or growth of our market or market share;


•	our ability to acquire companies, businesses, products or technologies on commercially reasonable terms and integrate such acquisitions effectively;


•	our continued investment in, and ability to deliver on, our key business strategies of developing differentiated solutions, increasing penetration of new markets, and expanding our solutions through acquisitions and partnerships;


•	our ability to deliver on our goals of advancing our platform with new product introductions annually and producing solutions that support fully digitized and automated central pharmacy operations;


•	our belief that continued investment in our key business strategies will continue to generate our revenues and earnings growth, as well as our expectations about the trends and other factors we believe will be critical to the success of our strategies;


•	the bookings, revenue, and margin opportunity presented by new products, emerging markets, and international markets;


•	our ability to align our cost structure and headcount with our current business expectations;


•	the operating margins or earnings per share goals we may set;


•	our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;


•	our expected future uses of cash and the sufficiency of our sources of funding;


•	the expected impacts of new accounting standards or changes to existing accounting standards;


•	the impacts of the U.S. Tax Cuts and Jobs Act of 2017; and


•	our ability to generate cash from operations and our estimates regarding the sufficiency of our cash resources.

In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “seeks,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” and variations of these terms and similar expressions. Forward-looking statements are based on our current expectations and assumptions, and are subject to known and unknown risks and uncertainties, which may cause our actual results, performance, or achievements to be materially different from those expressed or implied in the forward-looking statements.

Such risks and uncertainties include those described throughout this quarterly report, particularly in Part II - Item 1A. “Risk Factors” below. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. You should carefully read this quarterly report and the documents that we reference in this quarterly report and have filed as exhibits, as well as other documents we file from time to time with the Securities and Exchange Commission, with the understanding that our actual future results may be materially different from what we expect. All references in this report to “Omnicell,” “our,” “us,” “we,” or the “Company” collectively refer to Omnicell, Inc., a Delaware corporation, and its subsidiaries. The term “Omnicell, Inc.” refers only to Omnicell, Inc., excluding its subsidiaries. The forward-looking statements in this quarterly report represent our estimates and assumptions only as of the date of this quarterly report. Except as required by law, we assume no obligation to update any forward-looking statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, even if new information becomes available in the future.

Table of Contents

We own various trademarks and service marks used in our business, including the following registered and unregistered marks which appear in this report: Omnicell^®, the Omnicell logo, SureMed^®, Ateb^®, Time My Meds^®, Aesynt^®, AcuDose-Rx^®, Connect-Rx^®, MACH4^®, Anesthesia Workstation™, and Performance Center™. This report also includes the trademarks and service marks of other companies. All other trademarks and service marks used in this report are the marks of their respective holders.

OVERVIEW

Our Business

We are a leading provider of comprehensive automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home.

Operating Segments

We manage our business as two operating segments, Automation and Analytics and Medication Adherence:

•

Automation and Analytics. The Automation and Analytics segment is organized around the design, manufacturing, selling, and servicing of medication and supply dispensing systems; pharmacy inventory management systems; and related software. Our Automation and Analytics products are designed to enable our customers to enhance and improve the effectiveness of the medication-use process, the efficiency of the medical-surgical supply chain, overall patient care, and clinical and financial outcomes of medical facilities. Through modular configuration and upgrades, our systems can be tailored to specific customer needs.

•

Medication Adherence. The Medication Adherence segment primarily includes the development, manufacturing, and selling of solutions to assist patients to remain adherent to their medication regimens. These solutions are comprised of a variety of tools and aids that may be directly used by a pharmacist or a healthcare provider in their direct care for a patient, or the patient themselves, and include software-based systems, medi